Shawn D. Walker
Shawn D. Walker has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Matthew G. Beaver
Process Development, Amgen, Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
6 shared publications Sheng Cui
Drug Substance Technologies, Process Development, Amgen, Inc., Cambridge, Massachusetts 02142, United States
6 shared publicationsJacqueline C. S. Woo
Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
5 shared publicationsMargaret M. Faul
Drug Substance Technologies, Process Development, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
5 shared publicationsAyman Allian
Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
4 shared publicationsSeth Huggins
Process Development, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States
4 shared publications
Latest Publications
- 11 January 2021
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 25 (3) , 486-499
Implementing Continuous Manufacturing for the Final Methylation Step in the AMG 397 Process to Deliver Key Quality Attributes
- 11 January 2021
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 25 (3) , 486-499
Implementing Continuous Manufacturing for the Final Methylation Step in the AMG 397 Process to Deliver Key Quality Attributes
- 14 July 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (10) , 1891-1908
A Virtual Plant for Integrated Continuous Manufacturing of a Carfilzomib Drug Substance Intermediate, Part 3: Manganese-Catalyzed Asymmetric Epoxidation, Crystallization, and Filtration
- 14 July 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (10) , 1891-1908
A Virtual Plant for Integrated Continuous Manufacturing of a Carfilzomib Drug Substance Intermediate, Part 3: Manganese-Catalyzed Asymmetric Epoxidation, Crystallization, and Filtration
- 14 July 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (10) , 1861-1875
A Virtual Plant for Integrated Continuous Manufacturing of a Carfilzomib Drug Substance Intermediate, Part 1: CDI-Promoted Amide Bond Formation
- 14 July 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (10) , 1861-1875
A Virtual Plant for Integrated Continuous Manufacturing of a Carfilzomib Drug Substance Intermediate, Part 1: CDI-Promoted Amide Bond Formation
- 2 April 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (4) , 490-499
Continuous Process Improvement in the Manufacture of Carfilzomib, Part 2: An Improved Process for Synthesis of the Epoxyketone Warhead
- 2 April 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (4) , 490-499
Continuous Process Improvement in the Manufacture of Carfilzomib, Part 2: An Improved Process for Synthesis of the Epoxyketone Warhead
- 27 March 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (6) , 1164-1174
Development of a Robust and Highly Selective Ru(II)-Catalyzed Dynamic Kinetic Resolution Used to Manufacture AMG 232
- 27 March 2020
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 24 (6) , 1164-1174
Development of a Robust and Highly Selective Ru(II)-Catalyzed Dynamic Kinetic Resolution Used to Manufacture AMG 232
- 1 March 2020
- Published by Wiley in Israel Journal of Chemistry
- Vol. 60 (3-4) , 340-350
Accelerating Pharmaceutical Development via Metal‐Mediated Bond Formation
A perspective of our work on the development of practical metal‐mediated carbon‐carbon and carbon‐heteroatom bond forming processes within a modern drug portfolio is presented. The case studies selected from our laboratories highlight the synthetic challenges and opportunities presented by pharmaceutically relevant scaffolds. In many cases, the target structures challenged available synthetic methods and inspired the invention of enabling technology to accelerate drug development. Additionally, considerations for running metal‐mediated processes on large scale are discussed.
- 1 March 2020
- Published by Wiley in Israel Journal of Chemistry
- Vol. 60 (3-4) , 340-350
Accelerating Pharmaceutical Development via Metal‐Mediated Bond Formation
A perspective of our work on the development of practical metal‐mediated carbon‐carbon and carbon‐heteroatom bond forming processes within a modern drug portfolio is presented. The case studies selected from our laboratories highlight the synthetic challenges and opportunities presented by pharmaceutically relevant scaffolds. In many cases, the target structures challenged available synthetic methods and inspired the invention of enabling technology to accelerate drug development. Additionally, considerations for running metal‐mediated processes on large scale are discussed.
- 15 July 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (8) , 1558-1567
Development of a Factory Process for Omecamtiv Mecarbil, a Novel Cardiac Myosin Activator
- 15 July 2019
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 23 (8) , 1558-1567
Development of a Factory Process for Omecamtiv Mecarbil, a Novel Cardiac Myosin Activator
- 27 March 2019
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 84 (8) , 4583-4603
Molecular Complexity as a Driver for Chemical Process Innovation in the Pharmaceutical Industry
A Perspective of our work in the development of innovative synthetic methods within the discipline of Process Research and Development is presented. Through an overview of some of the programs that we have worked on during the past decade, we have selected cases studies to illustrate the challenges faced in development of robust chemical processes for molecules on a multi-kilogram scale. The examples have been selected to demonstrate the innovative chemistry being developed within our laboratories with a focus on fragment design, asymmetric synthesis, new synthetic reagents, and the methods that have allowed us to deliver cost-effective syntheses under reduced timelines in an increasingly competitive environment. The technical challenges are presented in the context of molecule complexity that while increasing in the portfolio of small molecules being developed inspires us to deliver new solutions. Overall, our goal is to highlight the exciting work that can be done within our field to support the discovery and delivery of medicines to patients.
- 27 March 2019
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 84 (8) , 4583-4603
Molecular Complexity as a Driver for Chemical Process Innovation in the Pharmaceutical Industry
A Perspective of our work in the development of innovative synthetic methods within the discipline of Process Research and Development is presented. Through an overview of some of the programs that we have worked on during the past decade, we have selected cases studies to illustrate the challenges faced in development of robust chemical processes for molecules on a multi-kilogram scale. The examples have been selected to demonstrate the innovative chemistry being developed within our laboratories with a focus on fragment design, asymmetric synthesis, new synthetic reagents, and the methods that have allowed us to deliver cost-effective syntheses under reduced timelines in an increasingly competitive environment. The technical challenges are presented in the context of molecule complexity that while increasing in the portfolio of small molecules being developed inspires us to deliver new solutions. Overall, our goal is to highlight the exciting work that can be done within our field to support the discovery and delivery of medicines to patients.